INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Stephen Farrand , Ph.D., former Merck executive appointed Senior Vice President Global Manufacturing CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 6, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using
View HTML
Toggle Summary NantKwest Announces Presentations at Upcoming Investment Conference Meetings
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- NantKwest Inc. (Nasdaq:NK) today announced that the company will be presenting at the following upcoming investment conferences in November and December: Citi 2015 Global Healthcare Conference, Jefferies 2015 Global Healthcare Conference and the
View HTML
Toggle Summary NantKwest Announces $50 Million Stock Repurchase Program
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 12, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Names Angela Wilson Chief Financial Officer
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 17, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the
View HTML
Toggle Summary NantKwest Announces Presentation at the American Society of Hematology (ASH) Annual Meeting; NK-92 Phase 1 Clinical Data on Dosing and Long-Term Survival in Relapsed Hematological Malignancies
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
View HTML
Toggle Summary NantKwest Announces Presentation of Preclinical Data of HER2.taNK at the San Antonio Breast Cancer Symposium (SABCS)
“Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer” CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 9, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
View HTML
Toggle Summary NantKwest Added to Nasdaq Biotechnology Index
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 18, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
View HTML
Toggle Summary NantKwest to Host Investor Day on January 14, 2016
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, announced today that
View HTML
Toggle Summary Nant Leaders to Share Vision of Cancer Moonshot 2020 Program at Premier Oncology Event
Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer) Phoenix – February 22, 2016 – NantWorks , LLC, NantKwest (Nasdaq: NK), and NantHealth , LLC  today announced the scheduled discussion topics
View HTML
Toggle Summary Patrick Soon-Shiong, MD, to Deliver Cancer Moonshot 2020 Keynote at Biocom Global Life Science Partnering Conference
La Jolla, CA – February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks , LLC, and leader of the Cancer MoonShot 2020 program, will deliver the keynote session, “Cancer Moonshot 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science
View HTML